Open Access

RIPK3 modulates sarcoma through immune checkpoint HAVCR2

  • Authors:
    • Chen Qian
    • Deluo Wu
    • Jianwei Du
  • View Affiliations

  • Published online on: September 13, 2022     https://doi.org/10.3892/ol.2022.13501
  • Article Number: 381
  • Copyright: © Qian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sarcomas is a complex group of malignant diseasse with undetermined molecular mechanisms. Receptor interacting serine/threonine kinase 3 (RIPK3) is a necroptosis‑ and apoptosis‑related marker that has been implicated in several immune‑associated diseases and aggressive malignant tumours. In the present study, publicly available transcriptome sequencing data were collected from The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research To Generate Effective Treatments (TARGET) databases and extensive data mining was performed, focusing on RIPK3 and its potential function in the modulation of gene expression and signaling pathways, immune checkpoints and cell infiltration. Analysis of TCGA and TARGET data revealed 603 up‑ and 260 downregulated genes in the higher RIPK3 expression group compared with the lower RIPK3 expression groups, with transmembrane channel like 8 and transmembrane protein 97 as the top up‑ and downregulated genes, respectively. Further pathway analysis revealed that the overexpressed genes were enriched in ‘cytokine‑cytokine receptor interaction’. Higher RIPK3 was found to be associated with improved survival, the immune checkpoint gene hepatitis A virus cellular receptor 2 (HAVCR2) and an improved response to immune blockade therapy. The potential modulation of HAVCR2 expression by RIPK3 was confirmed by reverse transcription‑quantiative PCR in KHOS and 143B human osteosarcoma cell lines. Immune cell infiltration analysis revealed that RIPK3 was positively associated with macrophage and monocyte infiltration, suggesting that RIPK3 executes its function through these immune cells. These findings led to the hypothesis that increased RIPK3 expression may result in improved survival, possibly by regulating the immune checkpoint HAVCR2. In conclusion, the present study comprehensively elucidated the RIPK3 profile with regard to sarcoma survival, transcriptome expression, immune checkpoint therapy and immune cell infiltration. These findings suggest that RIPK3 is potentially a therapeutic target for sarcoma.
View Figures
View References

Related Articles

Journal Cover

November-2022
Volume 24 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Qian C, Wu D and Du J: <em>RIPK3</em> modulates sarcoma through immune checkpoint <em>HAVCR2</em>. Oncol Lett 24: 381, 2022.
APA
Qian, C., Wu, D., & Du, J. (2022). <em>RIPK3</em> modulates sarcoma through immune checkpoint <em>HAVCR2</em>. Oncology Letters, 24, 381. https://doi.org/10.3892/ol.2022.13501
MLA
Qian, C., Wu, D., Du, J."<em>RIPK3</em> modulates sarcoma through immune checkpoint <em>HAVCR2</em>". Oncology Letters 24.5 (2022): 381.
Chicago
Qian, C., Wu, D., Du, J."<em>RIPK3</em> modulates sarcoma through immune checkpoint <em>HAVCR2</em>". Oncology Letters 24, no. 5 (2022): 381. https://doi.org/10.3892/ol.2022.13501